BETASERON
Considering BetaseronOn BetaseronUnderstanding MSMS Resource CenterSupport & Community
Considering BetaseronOn BetaseronUnderstanding MSMS Resource CenterSupport & Community
Considering BetaseronOn BetaseronUnderstanding MSMS Resource CenterSupport & Community
Considering BetaseronOn BetaseronUnderstanding MSMS Resource CenterSupport & Community
Considering BetaseronOn BetaseronUnderstanding MSMS Resource Center
Considering BetaseronOn BetaseronUnderstanding MSMS Resource CenterSupport & Community
StephanieStephanie: Betaseron Patient, California
Join ms pathways now

Do you or someone you care about have MS? MS PathwaysSM is the source for personalized B.E.T.A.SM Nurse support for BETASERON patients and those considering BETASERON therapy. Take advantage of the many helpful tools offered by MS PathwaysSM, including Injection Reminders to help you maintain the benefits of your medication.

HealthCare Professionals

MS Treatment Challenge

Adobe® Flash® Player required. Download the latest version here for free.
 

To learn more about BETASERON treatment, please see the Medication Guide.

Avonex is a registered trademark of Biogen Idec, Inc.; Rebif is a registered trademark of EMD Serono, Inc. Copaxone is a registered trademark of Teva Pharmaceutical Industries Ltd. See package inserts for each product.

Betaseron is a registered trademark and MS Pathways and B.E.T.A. are service marks of Bayer HealthCare Pharmaceuticals Inc.

BETASERON® (Interferon beta-1b) is indicated for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations. Patients with multiple sclerosis in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis.

Important Safety Information
The most commonly reported adverse reactions are lymphopenia, injection-site reaction, asthenia, flu-like symptom complex, headache and pain. Gradual dose titration and use of analgesics during treatment initiation may help reduce flu-like symptoms. BETASERON should be used with caution in patients with depression. Injection-site necrosis has been reported in 4% of patients in controlled trials. Patients should be advised of the importance of rotating injection sites. Female patients should be warned about the potential risk to pregnancy. Cases of anaphylaxis have been reported rarely. See "Warnings," "Precautions," and "Adverse Reactions" sections of full Prescribing Information.